According to a new study, deaths linked to overdose of opioid are increasing, however, individuals aged between 15 and 24 have undergone a fall in treatment from buprenorphine, a lifesaving drug.
Buprenorphine is approved for opioid addiction by the United States FDA. Researchers came to these deductions at the New York-based Columbia University College of Physicians and Surgeons by examining national data linked to the prescriptions of buprenorphine filled by individuals between the ages of 15 and 80.
A professor of psychiatry, medicine and law at Columbia University, Dr. Mark Olfson is also the leader of the research. Dr. Mark Olfson stated how the outcomes from the latest research showcase their progress from 2009 to 2018 through how the number of American citizens treated with buprenorphine rose to 1.1 million from 0.4 million.
But it was also observed how the use of the drub declined in the youngest age group to 1.40 for every 1,000 individuals from a previous 1.76 for every 1,000 individuals. This was a decline of nearly 20%.
The results also saw that the strength and duration of the prescription for buprenorphine also fell in the individuals belonging the 15 to 24 years age group relative to older U.S. citizens.
In a university news release, Dr. Mark Olfson stated how the results seen in younger individuals are particularlu concerning, provided that their fall in the treatment by buprenorphine took place during a time when there was a rise in the number of deaths owed to opioid overdose in this age group.
The UCSF Professor of Emergency Medicine and Clinical Pharmacy at UCSF Fresno and Medical Director of the Fresno/Madera Division of the California Poison Control System, Dr. Rais Vohra stated that a reason that treatment through buprenorphine isn’t rising in youngsters in that most centers of addiction as psychiatrists focus on treating adults.